Alterity Therapeutics Submits Application for Quotation of Securities

Alterity Therapeutics Limited filed a Form 6-K with the SEC on August 3, 2026, announcing an application for the quotation of securities (ATH). The filing includes Exhibit 99.1, which serves as the formal application for the quotation of these securities. This administrative filing indicates the company is seeking to list or quote additional securities on the relevant exchange. The document is incorporated by reference into several of the company’s existing Registration Statements on Form S-8 and Form F-3. No specific clinical data, trial results, or financial figures were disclosed in this brief regulatory notification. The filing was signed by Julian Babarczy, Chairman of Alterity Therapeutics. The company continues its activities as a development-stage biotechnology enterprise.